Tyrosine kinase inhibitors

1 . A compound of Formula I:

Wherein:

R 1a and R 1b are independently selected from:

1) hydrogen,

2) unsubstituted or substituted C 1 -C 10 alkyl,

3) OR 3 ,

4) N(R 3 ) 2 ,

5) unsubstituted or substituted aryl,

6) unsubstituted or substituted heterocycle, and

7) unsubstituted or substituted C 3 -C 10 cycloalkyl;

R 1c is independently selected from:

1) hydrogen,

2) C 1 -C 10 alkyl,

3) OR 3 ,

4) N(R 3 ) 2 ,

5) C 3 -C 10 cycloalkyl,

6) aryl, and

7) heterocycle;

said alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R 7 ;

R 2 is independently selected from:

1) hydrogen,

2) unsubstituted or substituted C 1 -C 10 alkyl,

3) N(R 3 ) 2 ,

4) OR 3 ,

5) unsubstituted or substituted aryl, and

6) unsubstituted or substituted C 3 -C 10 cycloalkyl;

R 3 is independently selected from:

1) hydrogen,

2) C 1 -C 10 alkyl,

3) aryl,

4) heterocycle,

5) C 3 -C 10 cycloalkyl,

6) CF 3 ,

7) C 2 -C 6 alkenyl,

8) C 2 -C 6 alkynyl,

9) S(O) m R 6 , and

10) C(O)R 6 ;

said alkyl, cycloalkyl, aryl, heterocycle, alkynyl, and alkenyl is optionally substituted with at least one substituent selected from R 7 ;

R 5 is independently selected from:

1) hydrogen,

2) halogen,

3) —(CR 1c 2 ) n OR 3 ,

4) —(CR 1c 2 ) n R 6 ,

5) —C(O)OR 3 ,

6) —C(O)R 3 ,

7) —C≡CR 3

8) —R 3 C═C(R 3 ) 2 ,

9) —OS(O) m R 6 ,

10) —NO 2 ,

11) —(CR 1c 2 ) n N(R 3 ) 2 ,

12) —N(R 3 )C(O)R 3 ,

13) —N(R 3 )S(O) m R 6 ,

14) —(CR 1c 2 ) n NR 3 (CR 1c 2 ) n C(O)NR 32 ,

15) —O(CR 1c 2 ) n C(O)N(R 3 ) 2 ,

16) —O(CR 1c 2 ) n C(O)OR 3 ,

17) —NR 3 (CR 1c 2 ) n N(R 3 ) 2 ,

18) —(CR 1c 2 ) n NR 3 R 6 OR 3 ,

19) —S(O) m R 6 ,

20) —S(O) m N(R 3 ) 2 ,

21) —CN,

22) —(CR 1c 2 ) n N(R 3 )(CR 1c 2 ) n R 6 , and

23) —(CR 1c 2 ) n C(O)N(R 3 ) 2 ;

R 6 is independently selected from:

1) C 1 -C 10 alkyl,

2) C 3 -C 10 cycloalkyl,

3) aryl, and

4) heterocycle;

said, alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R 7 ;

R 7 is independently selected from:

1) hydrogen,

2) unsubstituted or substituted C 1 -C 10 alkyl,

3) unsubstituted or substituted C 3 -C 10 cycloalkyl,

4) unsubstituted or substituted aryl,

5) halogen,

6) OR 3 ,

7) CF 3 ,

8) unsubstituted or substituted heterocycle,

9) S(O) m N(R 3 ) 2 ,

10) C(O)OR 3 ,

11) C(O)R 3 ,

12) CN,

13) C(O)N(R 3 ) 2 ,

14) N(R 3 )C(O)R 3 ,

15) S(O) m R 6 , and

16) NO 2 ;

Y and Z are independently selected from:

1) hydrogen,

2) R 6 ,

3) OR 3 ,

4) N(R 3 ) 2 ,

5) C(O)OR 3 ,

6) C(O)N(R 3 ) 2 ,

7) C(O)R 3 ,

8) halogen,

9) N(R 3 )(CR 1c 2 ) n C(O)N(R 3 ) 2 ,

10) S(O) m N(R 3 ) 2 ,

11) N(R 3 )C(O)OR 3 ,

12) N(R 3 )S(O) m R 6 ,

13) N(R 3 )C(O)R 3 ,

14) N(R 3 )(CR 1c 2 ) n R 3 ,

15) S(O) m R 6 ,

16) R 6 S(O) m N(R 3 ) 2 ,

17) R 6 S(O) m R 6 ,

18) N(R 3 )S(O) m (CR 1c 2 ) n R 6 ,

19) N(R 3 )S(O) m R 6 OR 3 ,

20) N(R 3 )C(O)N(R 3 ) 2 ,

21) N(R 3 )C(O)R 6 OR 3 ,

22) N(R 3 )(CR 1c 2 ) n R 6 OR 3 ,

23) N(R 3 )OR 3 , and

24) N(R 3 )S(O) m R 6 NO 2 ;

m is independently 0, 1 or 2;

n is independently 0 to 6;

s is 0 to 6;

t is 0 to 6;

w is 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2 . The compound according to claim 1 ,

wherein:

R 1a and R 1b are independently selected from:

1) hydrogen,

2) unsubstituted or substituted C 1 -C 10 alkyl,

3) unsubstituted or substituted aryl,

4) unsubstituted or substituted heterocycle, and

5) OR 3 ;

R 1c is independently selected from:

1) hydrogen,

2) C 1 -C 10 alkyl,

3) OR 3 ,

4) N(R 3 ) 2 ,

5) aryl, and

6) heterocycle;

said alkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R 7 ;

R 2 is:

1) H,

2) unsubstituted or substituted alkyl,

3) OR 3 , or

4) N(R 3 ) 2 ;

R 3 is independently selected from:

1) hydrogen,

2) C 1 -C 10 alkyl,

3) aryl,

4) heterocycle,

5) C 3 -C 10 cycloalkyl,

6) CF 3 ,

7) S(O) m R 6 , and

8) C(O)R 6 ;

said alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R 7 ;

R 5 is independently selected from:

1) hydrogen,

2) halogen,

3) —OR 3 ,

4) —C(O)OR 3 ,

5) —C(O)R 3 ,

6) —C≡CR 3 ,

7) —R 3 C—C(R 3 ) 2 ,

8) —OS(O) m R 6 ,

9) —NO 2 ,

10) —N(R 3 ) 2 ,

11) —N(R 3 )C(O)R 3 ,

12) —N(R 3 )S(O) m R 6 ,

13) —(CR 1c 2 ) n NR 3 (CR 1c 2 ) n C(O)NR 32 ,

14) —O(CR 1c 2 ) n C(O)N(R 3 ) 2 ,

15) —O(CR 1c 2 ) n C(O)OR 3 ,

16) —NR 3 (CR 1c 2 ) n N(R 3 ) 2 ,

17) —(CR 1c 2 ) n NR 3 R 6 OR 3 ,

18) —S(O) m R 6 ,

19) —S(O) m N(R 3 ) 2 ,

20) —CN, and

21) —(CR 1c 2 ) n N(R 3 )(CR 1c 2 ) n R 6 ;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3 . The compound according to claim 2 ,

wherein:

R 1a and R 1b are independently selected from hydrogen, unsubstituted or substituted C 1 -C 10 alkyl, OR 3 , and unsubstituted or substituted aryl;

R 1c is independently selected from:

1) hydrogen,

2) C 1 -C 10 alkyl,

3) OR 3 , and

4) aryl;

said alkyl and aryl is optionally substituted with at least one substituent selected from R 7 ;

R 2 is:

1) OR 3 , or

2) N(R 3 ) 2 ;

R 5 is independently selected from:

1) hydrogen,

2) (CR 1c 2 ) n R 6 ,

3) halogen,

4) —(CR 1c 2 ) n OR 3 ,

5) —C(O)OR 3 ,

6) —C(O)R 3 ,

7) —C≡CR 3

8) —R 3 C═C(R 3 ) 2 ,

9) (CR 1c 2 ) n C(O)N(R 3 ) 2 , and

10) (CR 1c 2 ) n N(R 3 ) 2 ;

Y is:

1) hydrogen,

2) R 6 ,

3) OR 3 ,

4) C(O)R 3 ,

5) C(O)N(R 3 ) 2 , or

6) N(R 3 ) 2 ;

Z is:

1) hydrogen,

2) R 6 ,

3) OR 3 ,

4) N(R 3 ) 2 ,

5) C(O)OR 3 ,

6) C(O)N(R 3 ) 2 ,

7) C(O)R 3 ,

8) halogen,

9) N(R 3 )(CR 1c 2 ) n C(O)N(R 3 ) 2 ,

10) S(O) m N(R 3 ) 2 ,

11) N(R 3 )C(O)OR 3 ,

12) N(R 3 )S(O) m R 6 ,

13) N(R 3 )C(O)R 3 ,

14) N(R 3 )(CR 1c 2 ) n R 3 , or

15) S(O) m R 6 ;

n is independently 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4 . A compound selected from:

5-Chloro-3-[(methylamino)sulfonyl]-1H-indole-2-carboxamide;

3-(Aminosulfonyl)-5-chloro-1H-indole-2-carboxamide;

5-Bromo-3-({methyl[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;

3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-iodo-1H-indole-2-carboxamide;

3-[(Dimethylamino)sulfonyl]-5-methoxy-1H-indole-2-carboxamide; —Chloro-3-{[(2-phenethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-[(benzylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(cyclohexylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(1-naphthylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-{[(3-phenylpropyl)amino]sulfonyl}-1H-indole-2-carboxamide; —Chloro-3-[(ethylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(propylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(butylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(pentylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-{[ethyl(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-[(diethylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(iso-propylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(cyclobutylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(cyclopentylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-{[(4-chlorophenyl)amino}sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-{[(3-chlorophenyl)amino}sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-{[(2-chlorophenyl)amino}sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-{[(4-chlorophenyl)methylamino}sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-{[(3-chlorophenyl)methylamino}sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-{[(2-chlorophenyl)methylamino}sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(tert-butylamino)sulfonyl]-1H-indole-2-carboxamide;

(±)-5-Chloro-3-[(pyrrolidin-3-ylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(piperidin-4-ylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-{[(1-methyl-1H-benzimidazol-2-yl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-[(benzamideamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(5-aminotetrazole)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(pyridin-4-ylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-[(pyridin-2-ylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Chloro-3-{[(2-methyoxyethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-[(dimethylamino)sulfonyl]-1H-indole-2-carboxamide;

3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-chloro-1H-indole-2-carboxamide;

5-Chloro-3-{[(2-hydroxyethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-{[(2-morpholin-4-ylethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-{[(2-methoxyethyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[({[2-(2-acetamide)amino]ethyl}amino)sulfonyl]-1H-indole-2-carboxamide;

N-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}-N-methyl-β-alaninamide;

5-Bromo-3-[(methylamino)sulfonyl]-1H-indole-2-carboxamide;

Ethyl N-{[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}N-methyl-β-alaninate;

5-Bromo-3-{[cyclopropyl(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

(±)-5-Bromo-3-{[methyl(tetrahydrofuran-3-yl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-({methyl[2-(1H-1,2,4-triazol-1-yl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-{[methyl(tetrahydro-2H-pyran-4-yl)amino]sulfonyl}-1H-indole-2-carboxamide;

(±)-5-Bromo-3-{[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

3-({[4-(Aminosulfonyl)benzyl]amino}sulfonyl)-5-bromo-1H-indole-2-carboxamide;

5-Chloro-3-{[iso-propyl(2-methoxyethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

3-{[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl}-5-hydroxy-1H-indole-2-carboxamide;

3-{[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl}-5-methoxy-1H-indole-2-carboxamide;

5-Chloro-3-{[methoxy(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

(±)-5-Chloro-3-{[(2,3-dihydroxypropyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Chloro-3-{[(2-hydroxyethyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

N-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}-N-methylglycine;

N-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}-N-methylglycinamide;

5-Bromo-3-({[4-(methylsulfonyl)benzyl]amino}sulfonyl)-1H-indole-2-carboxamide;

3-[({2-[4-(Aminosulfonyl)phenyl]ethyl}amino)sulfonyl]-5-bromo-1H-indole-2-carboxamide;

3-{[(5-Amino-5-oxopentyl)amino]sulfonyl}-5-bromo-1H-indole-2-carboxamide;

3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-bromo-1H-indole-2-carboxamide;

tert-Butyl 2-({[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}amino)-ethylcarbamate;

3-{[(2-Aminoethyl)amino]sulfonyl}-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-[({ethylsulfonylamino}ethylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Iodo-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[methoxy(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Fluoro-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(4-nitrophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-({[2-({[(4-methoxyphenyl)amino]carbonyl}amino)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-[({3-[(4-chlorophenyl)thio]propyl}amino)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[({3-[(4-chlorophenyl)thio]propyl}amino)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[({3-[(4-chlorophenyl)sulfonyl]propyl}amino)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[({propylsulfonylamino}ethylamino)sulfonyl]-1H-indole-2-carboxamide hydrochloride;

5-Bromo-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[({2-[(phenylsulfonyl)amino]ethyl}amino)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[({2-[(methylsulfonyl)amino]ethyl}amino)sulfonyl]-1H-indole-2-carboxamide;

3-[({2-[(Benzylsulfonyl)amino]ethyl}amino)sulfonyl]-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(3-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(2,5-dimethoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(5-bromo-2-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-({[2-({[2-(trifluoromethoxy)phenyl]sulfonyl}amino)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(2-methoxy-5-methylphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(4-cyanophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(4-chlorophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(3,4-dimethoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[({3-[(phenylsulfonyl)amino]propyl}amino)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[(3-{[(4-methoxyphenyl)sulfonyl]amino}propyl)amino]sulfonyl}-1H-indole-2-carboxamide;

3-[({3-[(Benzylsulfonyl)amino]propyl}amino)sulfonyl]-5-bromo-1H-indole-2-carboxamide;

3-[({2-[(Aminocarbonyl)amino]ethyl}amino)sulfonyl]-5-bromo-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(4-bromophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[({2-[(thien-3-ylsulfonyl)amino]ethyl}amino)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(3-chlorobenzyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(2-phenylethyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-[({2-[(4-methoxybenzoyl)amino]ethyl}amino)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[({2-[(4-methoxybenzyl)amino]ethyl}amino)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[({2-[(4-methoxyphenyl)amino]ethyl}amino)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[({2-[(4-methoxyphenyl)(methylsulfonyl)amino]ethyl}amino)sulfonyl]-1H-indole-2-carboxamide;

3-[({2-[Acetyl(4-methoxyphenyl)amino]ethyl}amino)sulfonyl]-5-bromo-1H-indole-2-carboxamide;

5-Iodo-3-{[cyclopropyl(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Iodo-3-[(cyclopropylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Bromo-3-[(cyclopropylamino)sulfonyl]-1H-indole-2-carboxamide;

5-Iodo-3-{[methoxy(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

(±)-5-Chloro-3-{[(tetrahydro-2H-pyran-2-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

(±)-5-Bromo-3-{[(tetrahydro-2H-pyran-2-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

(±)-5-Iodo-3-{[(tetrahydro-2H-pyran-2-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

(±)-5-Chloro-3-{[methyl(tetrahydro-2H-pyran-2-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

(±)-5-Bromo-3-{[methyl(tetrahydro-2H-pyran-2-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

(±)-5-Iodo-3-{[methyl(tetrahydro-2H-pyran-2-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-Bromo-3-({[2-(tert-butylthio)ethyl]amino}sulfonyl)-1-H-indole-2-carboxamide;

5-chloro-3-{[methyl(tetrahydro-2H-pyran-4-yl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-chloro-3-({[1-(2,3-dihydro-1,4-benzodioxin-2-yl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-[(tetrahydro-2H-pyran-4-ylamino)sulfonyl]-1H-indole-2-carboxamide;

5-chloro-3-{[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-chloro-3-({[(3-methyloxetan-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-[(tetrahydrofuran-3-ylamino)sulfonyl]-1H-indole-2-carboxamide;

5-chloro-3-({[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-({[2-(3-phenyl-1H-1,2,4-triazol-5-yl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-({[2-(2-methoxyphenyl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-({[3-(trifluoromethyl)benzyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-({[2-(2,3-dihydro-1H-indol-1-yl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-({methyl[(1-methylpiperidin-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-{[(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(3-ethoxypropyl)amino]sulfonyl}-1H-indole-2-carboxamide;

3-[({[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}amino)methyl]-1-benzylpyrrolidine;

5-bromo3-({[(1-benzylpyrrolidin-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-{[(3-pyridin-3-ylpropyl)amino]sulfonyl}-1H-indole-2-carboxamide;

1-[2-({[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}amino)ethyl]-4-phenylpiperidine;

5-bromo-3-{[(3-cyclohexylpropyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(4,4-diphenylbutyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(3-butoxypropyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-7-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-({[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-({[3-(4-tert-butoxyphenyl)propyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-({[4-(4-tert-butoxyphenyl)butyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-{[(2-methoxy-1-methylethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(4-phenylbutyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-[({2-[(2,6-dichlorobenzyl)thio]ethyl}amino)sulfonyl]-1H-indole-2-carboxamide;

5-bromo-3-({[2-(tert-butylthio)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-[({6-[(4-chlorobenzyl)amino]-6-oxohexyl}amino)sulfonyl]-1H-indole-2-carboxamide;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5 . The compound according to claim 4 , that is selected from:

5-Chloro-3-{[ethyl(methyl)amino]sulfonyl}-1H-indole-2-carboxamide

(±)-5-Bromo-3-{[methyl(tetrahydrofuran-3-yl)amino]sulfonyl}-1H-indole-2-carboxamide

3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-bromo-1H-indole-2-carboxamide

5-Bromo-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide

5-bromo-3-{[(3-butoxypropyl)amino]sulfonyl}-1H-indole-2-carboxamide

5-bromo-3-({[3-(4-tert-butoxyphenyl)propyl]amino}sulfonyl)-1H-indole-2-carboxamide

5-chloro-3-({[2-(3-phenyl-1H-1,2,4-triazol-5-yl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide

or a pharmaceutically acceptable salt or stereoisomer thereof.

6 . A pharmaceutical composition which is comprised of a compound in accordance with claim 1 and a pharmaceutically acceptable carrier.

7 . A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of claim 1 .

8 . The method of claim 7 wherein the protein kinase is an RTK.

9 . The method of claim 8 , wherein the RTK is selected from IR, IGF-1R and IRR.

10 . A method of treating or preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of claim 1 .

11 . A method of claim 10 , wherein the PK-related disorder is an IGF-1R-related disorder selected from:

1) cancer,

2) diabetes,

3) an autoimmune disorder,

4) a hyperproliferation disorder,

5) aging,

6) acromegaly, and

7) Crohn's disease.

12 . A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of claim 1 .

13 . A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 .

14 . A method of treating cancer which comprises administering a therapeutically effective amount of a compound of claim 1 in combination with a second compound selected from:

1) an estrogen receptor modulator,

2) an androgen receptor modulator,

3) retinoid receptor modulator,

4) a cytotoxic agent,

5) an antiproliferative agent,

6) a prenyl-protein transferase inhibitor,

7) an HMG-CoA reductase inhibitor,

8) an HIV protease inhibitor,

9) a reverse transcriptase inhibitor, and

10) an angiogenesis inhibitor.

15 . The method of claim 14 , wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

16 . A method of treating cancer which comprises administering a therapeutically effective amount of a compound of claim 1 in combination with radiation therapy.

17 . The method of claim 16 wherein radiation therapy is also administered.

18 . A method of treating cancer which comprises administering a therapeutically effective amount of a compound of claim 1 and paclitaxel or trastuzumab.

19 - 21 . (canceled)

22 . A process for preparing an alkyl 5-iodo-1H-indole-2-carboxylate which comprises the steps of:

a) combining alkyl 1H-indole-2-carboxylate, iodine, sodium periodate and sulfuric acid in an alcohol, and heating to a temperature of about 50° C. to about 100° C. to obtain a product;

b) adding the product to a solution of organic solvent and aqueous solution to create a first biphasic mixture;

c) removing, drying, filtering and concentrating the organic layer;

d) dissolving the organic layer in an alcohol;

e) adding zinc and aqueous acid to produce a mixture;

f) combining the mixture with water to create a second biphasic mixture; and

g) extracting, drying and filtering the organic layer of the second biphasic mixture to obtain the alkyl 5-iodo-1H-indole-2-carboxylate.

23 . The process of claim 22 wherein the alkyl 5-iodo-1H-indole-2-carboxylate is ethyl 5-iodo-1H-indole-2-carboxylate.